Equity Research Diagnostics & Research

Should You Buy NeoGenomics, Inc. Stock in 2026?

By CirclFi Research Team · · Updated · 2/13 models active

According to the CirclFi Deep Alpha Valuation Engine, NeoGenomics, Inc. (NEO) occupies a solid middle-ground position with a Quality of Company score of 6.6/10. At the current market price of $16.51, the investment case depends heavily on whether our 13 independent valuation models indicate a discount to fair value.

The short answer: 1 of 2 CirclFi valuation models project upside for NeoGenomics, Inc. (NEO) at $16.50 — the models are evenly split, with a Quality Score of 6.6/10 and Value-Trap risk of 27/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • Models are split: 1 bullish vs 1 bearish
  • Quality Score: 6.6/10 — Moderate — mixed signals
  • Value Trap Risk: 27/100 — Low — manageable risk
  • Fair Value Range: $14.95 – $17.25 (15% spread)

Bullish Models

1 / 2

Bearish Models

1 / 2

Quality Score

6.6 /10

Moderate — mixed signals

Value Trap Risk

27 /100
Low

Low — manageable risk

Model Consensus

2 /13
Active Models

Avg. confidence: 29%

What Is the Investment Case for NeoGenomics, Inc. (NEO) in 2026?

What Is the Bull Case vs the Bear Case for NeoGenomics, Inc. (NEO)?

Bull case versus bear case for NeoGenomics, Inc. (NEO) at $16.50, derived from 2 active CirclFi valuation models on 2026-10-07.
Bull case — $17.25 target (+4.5%) Bear case — $14.95 target (-9.4%)
Industry tailwind: licensing and M&A optionality could provide meaningful support for NeoGenomics, Inc.'s revenue and margin trajectory in the Diagnostics & Research space. Industry headwind: generic/biosimilar competition represents a meaningful risk for NeoGenomics, Inc. and its Diagnostics & Research peers.

How Does NEO Compare to Its Diagnostics & Research Peers?

RDNT RadNet, Inc.
6.6
MYGN Myriad Genetics, Inc
6.5
XGN Exagen Inc.
6.7
BNR Burning Rock Biotech
6.5
PRPO Precipio, Inc.
6.7
WGS GeneDx Holdings Corp
6.4
XWEL XWELL, Inc.
5.5
MEDP Medpace Holdings, In
9.3

Valuation data pages: RDNT · MYGN · XGN · BNR · PRPO · WGS · XWEL · MEDP · WAT · IDXX

Which Other Stocks Score Like NEO on Quality?

Closest companies to NEO’s Quality of Company score of 6.6/10, across all industries.

Why Do CirclFi’s 2 Models Disagree on NEO?

Spread

15%

Fair Value Range

$14.95 – $17.25

A tight 15% spread suggests meaningful convergence, strengthening conviction in the composite estimate.

Most Bullish

Regime Cross

$17.25 (+4.5%)

Most Bearish

FTNN

$14.95 (-9.4%)

What Are the Biggest Risks of Buying NEO Stock?

Macro/Sector Risk

Diagnostics & Research headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View NEO Data Page →

So Is NeoGenomics, Inc. (NEO) Worth Buying in 2026?

NeoGenomics, Inc. at $16.51 is a genuine coin-flip in our framework. The 0–1 bull-bear split across 2 models, +14.0% model spread, and median fair value of $16.10 (-2.4% vs price) argue for a watchlist position rather than a high-conviction bet. Quality at 6.6/10 adds some comfort to the mix.

These are quantitative model outputs, not investment recommendations. NeoGenomics, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

What Else Do Investors Ask About NEO Stock?

Should I buy NEO stock right now?

Based on CirclFi's multi-model analysis, 1 of 2 models see upside for NEO at $16.50. The models are divided, which means the investment case depends heavily on your assumptions about NeoGenomics, Inc.'s future. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in NeoGenomics, Inc.?

Key risks include: limited model coverage (2/13 active), reducing analytical confidence; general market and sector-specific risks affecting Diagnostics & Research companies. Always diversify and consult a financial advisor.

How does NEO compare to its competitors?

Among Diagnostics & Research peers, NEO holds a Quality Score of 6.6/10. Comparable companies include RDNT (QOC 6.6), MYGN (QOC 6.5), XGN (QOC 6.7). The relative ranking helps investors identify whether NEO offers better fundamental quality than alternatives in the same sector.

Is NEO a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. NEO's Quality Score of 6.6/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.

What price should I buy NEO at?

CirclFi does not provide target buy prices or price alerts. However, our 2 active models produce fair value estimates ranging from $14.95 to $17.25. At $16.50, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for NEO.

View NEO Data Page Full Terminal — $60/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →